Al-Ahmadie Hikmat A, Olgac Semra, Gregor Polly D, Tickoo Satish K, Fine Samson W, Kondagunta G Varuni, Scher Howard I, Morris Michael J, Russo Paul, Motzer Robert J, Reuter Victor E
Department of Pathology, University of Chicago, Chicago, IL, USA.
Mod Pathol. 2008 Jun;21(6):727-32. doi: 10.1038/modpathol.2008.42. Epub 2008 Mar 14.
Prostate-specific membrane antigen is a type II membrane glycoprotein that is expressed in benign and neoplastic prostatic tissue and has been recently shown to be also expressed in the neovasculature of various solid malignant tumors including renal cell carcinoma. Renal cell carcinoma is a heterogeneous group of tumors with distinct morphologic and genetic characteristics and clinical behaviors. We performed immunohistochemical studies on formalin-fixed, paraffin-embedded archival material from 75 nephrectomies, using antibodies 13D6 against prostate-specific membrane antigen and CD31 against endothelial cells. The study included 30 clear cell renal cell carcinomas, and 15 of each of papillary and chromophobe renal cell carcinoma and oncocytoma. The extent and intensity of staining were assessed semiquantitatively. In all cases, immunoreactivity was detected only in the tumor-associated neovasculature and not in tumor cells. Clear cell renal cell carcinoma showed the most diffuse staining pattern, where 24/30 cases or 80% had >50% reactive vessels, followed by chromophobe renal cell carcinoma (9/15; 60%) and oncocytoma (5/15, 33%). No diffuse staining was detected in any of the papillary renal cell carcinomas and only focal staining was detected in 11 cases (11/15; 73%). Staining intensity was the strongest in clear cell renal cell carcinoma (25/30; 83%) followed by chromophobe renal cell carcinoma (9/15; 60%), oncocytoma (8/15, 53%) and papillary renal cell carcinoma (5/15; 33%). In summary, prostate-specific membrane antigen is expressed in tumor-associated neovasculature of the majority of renal cortical tumors and is most diffusely and intensely expressed in clear cell renal cell carcinoma and least in papillary renal cell carcinoma. The differences in the expression of prostate-specific membrane antigen in renal cell carcinoma subtypes provide further evidence of the biological diversity of these tumors, and diagnostic and therapeutic applications of such expression can be expanded to include subtypes of renal cell carcinoma.
前列腺特异性膜抗原是一种II型膜糖蛋白，在良性和肿瘤性前列腺组织中表达，最近还显示在包括肾细胞癌在内的各种实体恶性肿瘤的新生血管中也有表达。肾细胞癌是一组异质性肿瘤，具有不同的形态学、遗传学特征和临床行为。我们使用抗前列腺特异性膜抗原的抗体13D6和抗内皮细胞的CD31抗体，对75例肾切除术的福尔马林固定、石蜡包埋存档材料进行了免疫组织化学研究。该研究包括30例透明细胞肾细胞癌，以及各15例乳头状肾细胞癌、嫌色肾细胞癌和嗜酸细胞瘤。对染色的范围和强度进行半定量评估。在所有病例中，仅在肿瘤相关新生血管中检测到免疫反应性，而在肿瘤细胞中未检测到。透明细胞肾细胞癌显示出最弥漫的染色模式，其中24/30例（80%）有>50%的反应性血管，其次是嫌色肾细胞癌（9/15；60%）和嗜酸细胞瘤（5/15，33%）。在任何乳头状肾细胞癌中均未检测到弥漫性染色，仅在11例（11/15；73%）中检测到局灶性染色。染色强度在透明细胞肾细胞癌中最强（25/30；83%），其次是嫌色肾细胞癌（9/15；60%）、嗜酸细胞瘤（8/15，53%）和乳头状肾细胞癌（5/15；33%）。总之，前列腺特异性膜抗原在大多数肾皮质肿瘤的肿瘤相关新生血管中表达，在透明细胞肾细胞癌中表达最弥漫、最强，在乳头状肾细胞癌中表达最少。肾细胞癌亚型中前列腺特异性膜抗原表达的差异为这些肿瘤的生物学多样性提供了进一步证据，这种表达的诊断和治疗应用可扩展到包括肾细胞癌亚型。
